Carlyle, Brighton Park to invest $200 m in Indegene
February 02, 2021
To pick up minority stake in healthtech firm via primary, secondary deals The Carlyle Group and Brighton Park Capital will acquire a minority stake in Indegene, a Bengaluru-based enterprise healthtech solutions provider, for $200 million.
The transaction consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company, a press statement from Indegene said.
Founded in 1998 by first-generation entrepreneurs, Indegene is a transformation partner to the global life sciences industry. With more than 3,000 employees across North America, Europe, China, Japan and India, it provides technology platforms and commercialisation services to pharmaceutical, biotechnology and medical device companies.
Private equity firm Carlyle Group and Brighton Park Capital are investing $200 million in Indegene, the Bengaluru-headquartered enterprise healthtech solutions provider, for a minority stake. The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company. The firm did not reveal the valuation after this funding round. According to the sources, the valuation of Indegene has increased to about $700 million. Rising competition in the global pharmaceutical market is shifting business models and driving multi-year digital transformation programmes. Decisions are increasingly data-driven and leading healthcare enterprises are seeking partners with strong domain knowledge and modern technology skills as a result. Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the primary investment from Carlyle and Brighton Park to acce